The Association for the Accreditation of Human Research Protection Programs, Inc. announced the publication of a performance study on human research protection programs (HRPPs). The study is available in AAHRPP Advance and on the organization's Web site.
From data supplied by client organizations in 2009, AAHRPP has compiled an information database to help research organizations, researchers, sponsors, and government agencies identify and support high performance in HRPPs. One hundred ninety-six organizations, of which 8.7 percent were independent IRBs, 17.9 percent were hospitals, 27 percent were universities, 41.8 percent were VA medical centers, and 4.6 percent were other research organizations, submitted data. Following the demand for evidence-based practice in other areas, AAHRPP is leading an initiative to describe the current practices for human research protection for the research enterprise. The ultimate goal is to define and measure quality-in terms of both efficiency and the protections that organizations, IRBs, and researchers provide to research participants.
"The availability of objective data should drive bench-marking efforts to improve quality both within an organization and across the research enterprise," said Dr. Marjorie Speers, Ph.D., President and CEO. As part of the benchmarking process, individual organizations, both accredited and non-accredited, can compare their HRPPs to the aggregate of other accredited programs. Over time, they will be able to compare their current performance with their performance in the past.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.